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ABSTRACT
Hepatitis B and C are important causes of morbidity and mortality worldwide. In Brazil, according 
to the Ministry of Health, about 15% of population is infected by hepatitis B virus (HBV) and less 
than 1% by hepatitis C virus (HCV). Nevertheless, the age-specific prevalence of HBV and HCV 
markers remains unknown. This study aimed to determine the seroprevalence of HBV and HCV 
markers of infection and immunity in children and adolescents between 10 to 16 years old who live 
in the metropolitan area of Florianópolis, state of Santa Catarina, South of Brazil. Three hundred 
and eighty four individuals were enrolled in this study. Serological markers for HBV and HCV (HB-
sAg, total anti-HBc, anti-HBc IgM, anti-HBs and anti-HCV) were determined through Micropar-
ticle Enzyme Immunosorbant Assay (MEIA) - AxSYM System® - by using commercial diagnostic 
kits (Abbott Laboratories, Abbott Park, Illinois, USA). All 384 adolescents (100%) were negative for 
HBsAg and anti-HBc IgM. Only two (0.52%) were positive for total anti-HBc. Among the studied 
individuals, 226 (58.85%) presented titers of anti-HBs ≥ 10.0mIU/mL, 121 (31.51%) presented anti 
HBs < 10.0mIU/mL, and 37 (9.64%) did not present titers of anti-HBs. Regarding to anti-HCV, all 
384 adolescents (100%) presented negative results for this marker. In conclusion, this study showed 
a low prevalence of HBV and HCV infections. In addition, it was verified a great number of children 
and adolescents (89.84%) who were positive for the immunity marker anti-HBs, implying that the 
National Immunization Program Protocol for hepatitis B has been effective in the studied region. 
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Seroprevalence of hepatitis B and hepatitis C markers 
among children and adolescents in the south brazilian 
region - metropolitan area of Florianópolis, Santa Catarina
INTRODUCTION
Hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infections are the most common causes 
of liver disease worldwide.1 Both viruses can 
be transmitted parenterally, sexually and peri-
natally, with perinatal and sexual transmission 
being more common for HBV2,3 than for HCV.4 
Despite progress on prophylaxis, diagnostic and 
treatment of these infections, they still are one 
of the major causes of chronicle liver disease, 
such cirrhosis or hepatocellular carcinoma.5,6 
According to the World Health Organiza-
tion (WHO) it is estimated that, currently, 
more than 2 billion of the global population 
had been infected with HBV. Out of these, 
approximately 360 million are chronically in-
fected and at risk of serious illness and death 
from liver cirrhosis and liver cancer, diseases 
that are estimated to cause 500,000 to 700,000 
deaths each year worldwide.7
Also according to WHO estimates, about 
170 million people, 3% of the world’s popula-
tion, are infected with HCV and are at risk of 
developing liver cirrhosis and/or liver cancer.8 
In Brazil, the Ministry of Health estimates 
that 15% of the population have been in con-
tact with HBV and not less than 1% of the pop-
ulation has chronic disease.9 However, there are 
not many studies revealing the real prevalence 
of HCV among Brazilians.10 Data obtained 
from blood donor banks, in 2002, showed a 
different distribution of the illness among Bra-
zilian regions. In the North region was found 
an incidence of 0.62%, in the Northeast 0.55%, 
in the West-Center 0.28%, in the Southeast 
0.43% and in the South 0.46%.11 
Due to Brazilian’s territorial extension and 
its economic and cultural differences, hepati-
tis B and C infection rates are different in each 
region.11 Epidemiologic studies regarding to 
the distribution of these illnesses in Brazil are 
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uncommon. In general, such studies focus the incidence 
rather than prevalence, like in the study of Charles et al., 
which demonstrated the incidence of hepatitis B in the 
South region of Brazil from the year of 1997 to 1999.12 
The main reason for the predominance of incidence 
studies rest in the way how the data are collected. The 
term incidence refers to the number of new cases of in-
fection, emerged in a certain population, at determined 
interval of time. Therefore, incidence studies do not need 
deal with population directly, because this information 
is obtained from health public organization, like Epide-
miologic Vigilance. On the other hand, the prevalence is 
established by the total number of positive cases of in-
fection, in a certain population at specific time. And to 
get the prevalence rates, tests with population are needed. 
In fact, the difficulty in gathering the needful number 
of blood samples among the ordinary population is the 
main reason for this lack of prevalence studies.13 So, these 
studies are almost always performed in specific groups, 
like blood donors14-17 or HIV-seropositive patients.18,19 
Hepatitis B and C are important diseases and have seri-
ous consequences. Prevention is the best alternative to con-
trol their spreading. For hepatitis C there is not a vaccine, 
and its prevention is reached only by educational programs, 
but for hepatitis B vaccination exists and is essential. The 
prevention of hepatitis B by vaccination is one of the most 
efficient tools to avoid the transmission of the virus.
In 1989, the vaccination against hepatitis B began in 
some regions of Brazil, for specific groups. Some years 
later, it was enlarged to more regions and to children 
younger than one year old, as well as to high risk popu-
lations. Afterwards, the coverage of the vaccine was am-
plified for health students and militaries, and then, for 
adolescents up to 15 years old in some Federal States. Re-
garding specifically to Santa Catarina state, in 1993 the 
vaccination was recommended to children younger than 
four years old, and in 1996, to children up to fifteen years 
old. In 2001 the immunization was extended to whole 
Brazilian territory, comprehending the population up to 
nineteen years old.11 
This study aimed to determine the prevalence of HBV 
and HCV infections in children and adolescents between 
10 and 16 years old who live in the metropolitan area of 
Florianópolis, state of Santa Catarina, in South of Bra-
zil. For this purpose, serological assays of hepatitis B 
surface antigen (HBsAg), antibodies to hepatitis B core 
antigen (total anti-HBc and anti-HBc IgM), and hepatitis 
C antibody (anti-HCV) were performed. Moreover, one 
pretends to determine the prevalence of the marker for 
immunity to hepatitis B in the same population, using 
antibody to hepatitis B surface antigen (anti-HBs), allow-
ing one evaluates the effectiveness of the National Immu-
nization Program Protocol for hepatitis B.
MATERIAL AND METHODS 
The studied group was formed by children and adoles-
cents between 10 to 16 years old, residents in the metro-
politan area of Florianópolis, whose blood was tested, re-
gardless the reason, in the Clinical Analysis Laboratories 
of the same region. An additional amount of blood was 
drawn from the same venous puncture site used to collect 
the original sample for the testing assigned to the patient 
at the Clinical Analysis Laboratory. The blood samples 
were obtained between May 2007 and August 2008 in 14 
Clinical Analysis Laboratories distributed around the re-
gion of interest. 
The study was approved by the Ethical Committees 
of the Federal University of Santa Catarina (Project nº 
351/2006). A written informed consent was obtained 
from the legal responsible persons of each participant 
since all subjects were under the legal majority age (18 
years old).
The minimum number of samples n was defined by20
where α is the confidence interval, z is the corresponding 
value of α at normal curve, p is the probability of finding the 
studied phenomenon, q (q = 1-p) is the complementary part 
of probability, and E is the admissible error. In this study a 
confidence interval of 95% was adopted. Thus, α = 0.05 and 
z = 1.96. Unknown prevalence markers at studied popu-
lation makes p equals 50% (p = 0.5) and, consequently, 
q equals 0.5. The admissible error was bounded in 5% 
(E = 0.05). Using such criteria the minimum sample number 
was defined as 384, number reached at the end of the study.
The collected blood samples were centrifuged to sepa-
rate the serum, which was forwarded then to laboratorial 
analysis. Serological markers for HBV and HCV (HBsAg, 
total anti-HBc, anti-HBc IgM, anti-HBs and anti-HCV) 
were determined through Microparticle Enzyme Im-
munosorbant Assay (MEIA) - AxSYM System®, by using 
commercial diagnostic kits (Abbott Laboratories, Abbott 
Park, Illinois, USA) and following the instructions pro-
vided by the producer. All laboratory assays were per-
formed at the Clinical Analysis Laboratory of University 
Hospital of Federal University of Santa Catarina, in Flori-
anópolis. Then, prevalence of each serological marker was 
established according to sex. 
 
RESULTS
The main characteristics of the 384 children and adolescents 
are showed at Table 1. All 384 adolescents (100%) were neg-
ative for HBsAg (Table 2) and anti-HBc IgM (Table 3). Only 
two adolescents (0.52%) were positive for total anti-HBc 
(Table 4). Among the studied individuals, 226 (58.85%) 
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Table 1. Demographic study population
  Adolescents 
Sex  (n = 384)
 male 163 (42.45%)
 female 221 (57.55%)
Age at enrollment (years; mean ± D) 12.59 ± 2.02
residential location 
 Florianópolis 241 (62.76%)
 Metropolitan area 143 (37.24%)
Table 2. Prevalence of HBsAg according to sex
Sex HBsAg (+) HBsAg (-)
 male 0 (0%) 163 (42.45%)
 female 0 (0%) 221 (57.55%)
Total 0 (0%) 384 (100%)
*HBsAg: hepatitis B surface antigen
Table 3. Prevalence of anti-HBc IgM according to sex
Sex  anti-HBc IgM (+) anti-HBc IgM (-)
 male 0 (0%) 163 (42.45%)
 female 0 (0%) 221 (57.55%)
Total 0 (0%) 384 (100%)
*Anti-HBc IgM: antibody (immunoglobulin M) to hepatitis B 
core antigen 
Table 4. Prevalence of total anti-HBc according to sex
Sex total anti-HBc (+) total anti-HBc (-) Total
 male 2 (0.52%) 161 (41.93%) 163 (42.45%)
 female 0 (0%) 221 (57.55%) 221 (57.55%)
Total 2 (0.52%) 382 (99.48%) 384 (100%)
*Total anti-HBc: antibodies (immunoglobulin M and G) to  
 hepatitis B core antigen
Table 7. Prevalence of anti-HCV according to sex
Sex anti-HCV (+) anti-HCV (-)
 male 0 (0%) 163 (42.45%)
 female 0 (0%) 221 (57.55%)
Total 0 (0%) 384 (100%)
*Anti-HCV: hepatitis C antibody
Table 5. Prevalence of anti-HBs according to sex
Sex	 	 anti-HBs	=	0.0	mIU/mL	 0.0	>	anti-HBs	<	10.0mIU/mL	 anti-HBs	≥	10.0mIU/mL	 Total
 male 17 (4.43%) 50 (13.02%) 96 (25%) 163 (42.45%)
 female 20 (5.21%) 71 (18.49%) 130 (33.85%) 221 (57.55%)
Total 37 (9.64%) 121 (31.51%) 226 (58.85%) 384 (100%)
* Anti-HBs: antibody to hepatitis B surface antigen
Table 6. Comparison of HBV markers prevalence according to sex
  Total anti-HBc (+) Total anti-HBc (-) Total anti-HBc (-) 
Sex
 anti-HBc IgM (-) anti-HBc IgM (-) anti-HBc IgM (-) 
Total
  HBsAg (-) HBsAg (-) HBsAg (-) 
  anti-HBs (+) anti-HBs (-) anti-HBs (+) 
 male 2 (0.52%) 17 (4.43%) 144 (37.50%) 163 (42.45%)
 female 0 (0%) 20 (5.21%) 201 (52.34%) 221 (57.55%)
Total 2 (0.52%) 37 (9.64%) 345 (89.84%) 384 (100%)
*Total anti-HBc: antibodies (immunoglobulin M and G) to hepatitis B core antigen; *anti-HBc IgM: antibody (immunoglobulin M) 
to hepatitis B core antigen; *HBsAg: hepatitis B surface antigen; *anti-HBs: antibody to hepatitis B surface antigen
presented titers of anti HBs ≥ 10.0mIU/mL, 121 (31.51%) 
presented anti HBs < 10.0mIU/mL, and 37 (9.64%) did 
not present titers of anti-HBs (Table 5). Thirty seven in-
dividuals were negative for all HBV markers studied, 345 
(89.84%) were positive only for anti-HBs and 2 (0.52%) 
were positive for anti-HBs and total anti-HBc (Table 6). 
Regarding to anti-HCV, all individuals presented negative 
results for this marker (Table 7).
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DISCUSSION
According to the Ministry of Health, the South of Brazil 
is considered a low prevalence region of hepatitis B infec-
tion (less than 2% of population is positive for HBsAg). 
Nevertheless, there are exception for the west region of 
Santa Catarina, classified as a moderate prevalence region 
(between 2% and 7% of HBsAg positive) and the west of 
Paraná, which presents high prevalence levels (higher than 
7% of HBsAg positive) of hepatitis B infection.11 The few 
prevalence studies in Brazil have showed low numbers for 
its infection markers.13-15,17 Miranda et al.13 established prev-
alence of hepatitis B serological markers among 632 indi-
viduals submitted to blood tests in health centers of Ribeirão 
Preto, São Paulo. Such data were collected between 1994 and 
1995. They found 0.3% of prevalence for HBsAg, specifically 
found in two individuals aged more than 60 years. Regard-
ing to anti-HBc, it was found a prevalence of 13.9%. How-
ever, there was no case of positive anti-HBc in the age-group 
of 10 to 19 years old.
Furthermore, prevalence of HBV infection markers has 
been decreasing in last years.14,17,21 Silveira et al.,21 in a study 
of hepatitis B seroprevalence in Latin America, carried out 
in 1994 to 1997, described a wide range of seroprevalences 
in the different regions of Brazil, with a high rate in Man-
aus (21%), followed by Porto Alegre (7.5%), Rio de Janei-
ro (5.5%), and Fortaleza (1.2%). Rosini et al.17 estimated 
prevalence of serological markers for HBV infection among 
blood donors in Santa Catarina in the years of 1999, 2000 
and 2001. They found HBsAg prevalence of 0.98% (1999), 
0.84% (2000) and 0.64% (2001), and anti-HBc prevalence 
of 8.83% (1999), 7.09% (2000) and 5.35% (2001). 
Recently, the Brazilian Ministry of Health, with some 
Universities’ help, had realized a seroprevalence study about 
viral hepatitis, in the capital of each state. Some results were 
already presented.22 According to this inquiry, in the South 
region, an anti-HBc prevalence of 1.18% was found for ado-
lescents between 10 and 19 years old, and 11.2% for adults 
between 20 and 69 years old. For anti-HBs, the prevalence 
were 0.12% for adolescents, and 0.5% for adults. 
The results represent prevalence of hepatitis B in urban 
population, and in this case attention is needed, since it is 
fact that higher prevalence usually is found in countryside, 
especially Amazon region, south of Espírito Santo, west of 
Paraná and Santa Catarina, regions not contemplated at the 
study.22
In the present study, a very low prevalence of HBV infec-
tion was found, like in the studies presented before. Only two 
individuals (0.52%) presented an infection marker of hepati-
tis B (total anti-HBc) positive. Furthermore, they presented 
negative results for anti-HBc IgM and HBsAg. The anti-HBc 
IgM negative means that contact was not recent, whereas 
the HBsAg negative means that virus was depurated of the 
organism. Such results characterize a past cured infection. 
Regarding to immunity, the majority of the studied 
population in this work (58.85%) presented titers of anti-
HBs ≥ 10.0mIU/mL, criterion adopted to establish protec-
tive concentrations.23-25 Moreover, 31.51% of the individuals 
presented anti HBs < 10.0mIU/mL. The remainder 9.64% 
did not present titers of anti-HBs. 
The anti-HBs is responsible for the immunity against 
HBV. In addition to cured infections, it is generally ac-
quired through vaccination. Primary vaccination with 
a three-dose series of hepatitis B vaccine results in sero-
protection (defined as the development of anti-HBs at a 
concentration greater than 10 mille International Units 
per milliliter [mIU/mL]) in > 95% of vaccinated infants 
and children.23-25 However, following completion of the 
primary series, anti-HBs concentrations decline and may 
fall below 10.0mIU/mL after several years. Despite the cri-
terion adopted to establish protective concentrations of 
anti-HBs (≥ 10.0mIU/mL), recent studies argue the immu-
nologic memory would be capable of preventing chronic 
or symptomatic infections even after anti-HBs declines to 
undetectable concentrations in vaccinated ones.26-34 
Based on previous discussion, one concludes that all in-
dividuals in this study, who presented positive titers of anti 
HBs and were negative for infection markers (89.84%), may 
have been vaccinated (Table 6). However, the sample was not 
random and is not population-based, so it could not be rep-
resentative of the population. Concerning to Brazilian Im-
munization Program, the vaccination coverage for hepatitis 
B in the state of Santa Catarina has reached 95% in the last 
years, for infants under one year old. On the other hand, the 
range of vaccination coverage for children and adolescents is 
not available for this population.35 
The Secretariat of Epidemiologic Vigilance, department 
subordinate to the Brazilian Ministry of Health, does not 
have a database referent to the vaccination program. Perti-
nent information such as who was vaccinated, whether the 
vaccination schedule was completed and when it was accom-
plished can be obtained just through vaccination cards. Since 
the majority of the adolescents enrolled in this study did not 
present the vaccination cards, it is not know if individuals 
without titers of anti-HBs (9.64%) represent not-vaccinated 
individuals, if they were vaccine primary nonresponders or 
if their antibodies titers declined over time. Even though 
the vaccination cards were available, it would not be possi-
ble to have sure about this information, because Secretariat 
of Health does not have control in the expedition of these 
cards, and it is common people have more than one.
On the other hand, the prevalence rates found in the 
present study (Table 5) are very similar to those showed in 
Italy,31 in which among 1,212 vaccinated children (mean age 
10.9 years), 64% presented titers of anti-HBs ≥ 10.0mIU/
mL, 27% presented antibody titers less than 10.0mIU/mL, 
and 9% presented undetectable amounts. Regarding to 
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infection markers, only one child presented anti-HBc posi-
tive in the Italian study,31 compared to two found in ours. In 
both studies, there was no case of HBsAg positive.
Regarding to HCV infection, in the present study, all 
384 adolescents (100%) were negative for this marker (an-
ti-HCV), which means none infection case in the studied 
population. Such result was not surprising due to the HCV 
modes of transmission and the age-group of the studied 
population. In fact, one of the few Brazilian’s studies about 
hepatitis C prevalence, carried out in São Paulo, demon-
strated an estimated HCV prevalence of 1.42%. This specific 
infection occurred more frequently among adults 30 years 
of age or older, with the prevalence reaching a peak of 3.80% 
among the group aged 50 to 59 years.36 In addition, Rosini 
et al.17 estimated the anti-HCV prevalence among blood do-
nors in Santa Catarina, in the years of 1999, 2000 and 2001. 
They found a prevalence of 0.41% in Florianópolis region; 
number a little bit higher than found in the state of Santa 
Catarina as a whole (0.35%).
The lack of data relative to child and adolescents in Bra-
zil makes difficult a deep comparison of the results obtained 
in this study. Most of studies deal with specific groups. The 
prevalence found in studies with blood donors, for example, 
refers to an age-group higher than the object of the present 
study, since the minimum age for blood donor is 18 years 
old. On the other hand, HIV seropositive groups are not 
good representatives for a population in general because 
they refer to a group of individuals with a high risk of HBV 
and HCV infection due to the common modes of transmis-
sion between such diseases. Hence, more studies with chil-
dren and adolescents are needed to confirm the results ob-
served in the present study. 
However, the recent Ministry of Health’s inquiry brings 
some information regarding to anti-HCV. A prevalence of 
1.63% for adolescents between 10 and 19 years old, and of 
1.98% for adults between 20 and 69 years old were found. 
For HCV, there are not studies revealing differences on 
prevalence in countryside compared to cities located at big 
urban centers.24
Despite the uncertainties, the results observed in this 
study reveal a good perspective for the future. A low preva-
lence of HBV and HCV infection and a high prevalence 
of HBV immunity among children and adolescents show 
progress towards the control of hepatitis B and C infections 
in Brazil. However, it is important to keep or even improve 
educational programs, especially because there is not a vac-
cine for the HCV prevention. As a matter of fact, diseases 
which have the same mode of transmission, like hepatitis 
B, hepatitis C and AIDS, could share the same prevention 
campaigns.
CONCLUSION
In conclusion, this study showed a low seroprevalence of 
HBV and HCV infections among children and adolescents 
in the metropolitan area of Florianópolis, Santa Catarina, 
South of Brazil. In addition, a large number of individuals 
presented titers of the seroprotection marker anti-HBs, im-
plying that National Immunization Program Protocol for 
hepatitis B has been effective in the studied region. Besides 
low prevalence of HBV and HCV infections, prevention 
campaigns are important to remind children and adoles-
cents how these infections can be prevented, mainly HCV, 
which does not have a vaccine for its prevention.
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